MorphoSys to Present at Three Investor Conferences in May
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Present at Three Investor Conferences in May
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
management will present at three international investor conferences in May.
Deutsche Bank 37(th) Annual Healthcare Conference
Date: May 07, 2012, 10:00 am EDT (04:00 pm CEST, 03:00 pm BST)
Venue: Boston, USA
Participants: Dr. Simon Moroney, CEO of MorphoSys AG; Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & IR
Deutsche Bank German, Swiss & Austrian Conference
Date: May 14 - May 16, 2012
Venue: Frankfurt, Germany
Participants: Jens Holstein, CFO of MorphoSys AG; Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & IR
BioEquity Europe 2012
Date: May 16, 2012, 09:30 am CEST (03:30 am EDT, 08:30 am BST)
Venue: Frankfurt, Germany
Participants: Jens Holstein, CFO of MorphoSys AG; Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & IR
The PDF version of the presentation will be provided at www.morphosys.com. Links
to the webcast, if available, are filed under www.morphosys.com/conference-
calls.
On May 31, 2012, the Annual General Meeting 2012 of MorphoSys AG will take place
in Munich. The management's presentation (in German) will be broadcasted online
at
10:00 am CEST under www.morphosys.com/agm.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
Company's AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more than
70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis, and Alzheimer's disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development, MorphoSys is focused
on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt
Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit
http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), Ylanthia(®), CysDisplay(®),
RapMAT(®) and arYla(®) are registered trademarks of MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1608858/510754.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1608858]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.05.2012 - 09:00 Uhr
Sprache: Deutsch
News-ID 1110819
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 89 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Present at Three Investor Conferences in May
"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
